275375-59-2

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 275375-98-9 2-chloro-6,8-dihydro-6-hydroxy-11-(trifluoromethyl)-7H-[1]benzopyrano[3,4-c]quinolin-7-one 
• 275375-96-7 N-[2-(5-chloro-2-hydroxy-benzoyl)-4-trifluoromethyl-phenyl]-malonamic acid methyl ester 
• 275375-97-8 2-chloro-6,8-dihydro-11-(trifluoromethyl)-7H-[1]benzopyrano[3,4-c]quinolin-6,7-dione 

Downstream Products

• 275375-62-7 4-(5-Chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinepropanoic acid, ethyl ester 

Relevant academic research and scientific papers

4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: Novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction

Novel 4-aryl-3-(hydroxyalkyl)quinoline-2-one derivatives were prepared and evaluated as openers of the cloned maxi-K channel hSlo expressed in Xenopus laevis oocytes by utilizing electrophysiological methods. The effect of these maxi-K openers on corporal

3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS

The present invention provides novel 3-substituted-4-arylquinolin-2-one derivatives having the general formula wherein R, R 1, R 2, R 3, R 4, R 5, R 6 and R 7 are as defined herein, or a non-toxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium-activated K + channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.